Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus V CILLIN.
PIPERACILLIN AND TAZOBACTAM vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Penicillin Antibiotic